What Is The Current and Historic Market Size Analysis Of The Whole Exome Sequencing Market?
The whole exome sequencing market has seen considerable growth due to a variety of factors.
•Recent times have seen a swift expansion of the entire exome sequencing market. The market, which was worth $2.82 billion in 2024, is expected to escalate to $3.37 billion in 2025, harnessing a compound annual growth rate (CAGR) of 19.4%.
Factors contributing to this upward trend during the historic period include enhancements in genomic research, changing trends in precision medicine, diagnosis of rare diseases, application in pharmaceutical and biotech industries, and a general reduction in sequencing costs.
What Are The Predictions for The Whole Exome Sequencing Market Size In The Coming Years?
The whole exome sequencing market is expected to maintain its strong growth trajectory in upcoming years.
• The entire exome sequencing market is projected to experience significant escalation in the coming years. With a Compound Annual Growth Rate (CAGR) of 21.3%,
the market is estimated to inflate to "$7.29 billion by 2029. Plenty of factors contribute to the growth during the forecasted period, including broader applications in the field of oncology, incorporation into clinical diagnostics, an increase in demand for genetic testing, initiatives towards population genomics, and the advent of gene therapies. Anticipated trends during this period encapsulate enhanced clinical usage and adoption, declining sequencing costs, emphasis on data protection and confidentiality, amalgamation with electronic health records, and advancements in single-cell sequencing.
Which Key Drivers Are Propelling The Whole Exome Sequencing Market's Growth?
The surge in human immunodeficiency virus (HIV) cases is projected to catalyze the expansion of the whole exome sequencing market. HIV is a virus that attacks the body's immune system. Whole exome sequencing contributes to the identification of the genomic structures of viruses, which are crucial for developing personalized treatments and vaccines for HIV. For example, as per the US government agency, the Minority HIV/AIDS Fund (MHAF), it was estimated that, in 2023, almost 39.9 million people across the globe had HIV, inclusive of 38.6 million adults and 1.4 million children. This was a rise in comparison to previous years. Consequently, the escalating prevalence of HIV is fuelling the growth of the whole exome sequencing market.
What Are The Key Segments Within The Global Whole Exome Sequencing Market?
The whole exome sequencing market covered in this report is segmented –
1) By Product: Systems, Kits, Services
2) By Technology: Sequencing By Synthesis, Ion Semiconductor Sequencing, Other Technologies
3) By Application: Diagnostics, Drug Discovery And Development, Personalized Medicine, Agriculture And Animal Research
4) By End-User: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Academic and Research Institutes, Clinical Laboratories, Other End-Users
Subsegments:
1) By Systems: Sequencing Systems, Data Analysis Systems
2) By Kits: Library Preparation Kits, Exome Enrichment Kits, Sequencing Kits
3) By Services: Data Analysis Services, Consulting Services, Custom Sequencing Services
Pre-Book The Whole Exome Sequencing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Whole Exome Sequencing Market?
The emergence of innovative diagnostic methods is becoming a notable trend in the whole exome sequencing market. Companies in this market are striving to maintain their competitive edge by developing innovative new products. For instance, Illumina Inc., a biotech firm based in the United States, unveiled NovaSeqX Plus, a highly powerful sequencing technology, in February 2023. The technology boasts unparalleled high throughput and precision and incorporates improved informatics, economic sequencing, and sustainability developments. The enhancements incorporated in the NovaSeq X Plus systems have the capability to produce tens of thousands of whole genomes annually, optimizing productivity and reducing wait times.
Who Are the Key Players in the Whole Exome Sequencing Market?
Major companies operating in the whole exome sequencing market include:
• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Eurofins Genomics
• Azenta US Inc.
• CD Genomics
• Psomagen Inc.
• Agilent Technologies
• BGI Genomics
• F. Hoffmann-La Roche Ltd.
• QIAGEN Inc.
• Macrogen Inc.
• Ambry Genetics
• Bio-Rad Laboratories Inc.
• Bioneer Corporation
• Foundation Medicine Inc.
• KONICA MINOLTA INC.
• Otogenetics Corporation
• Geneyx Genomex Ltd.
• ArcherDX Inc.
• Blueprint Genetics Oy
• Bionano Genomics Inc.
• Centogene AG
• Fulgent Genetics Inc.
• Natera Inc.
• GeneDx Inc.
• GENEWIZ Inc.
• Novogene Corporation
• PerkinElmer Inc.
• Personalis Inc.
What are the Regional Insights into the Whole Exome Sequencing Market?
North America was the largest region in the whole exome sequencing market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global whole exome sequencing market report during the forecast period. The regions covered in the whole exome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
